Publication Month: Aug 2018 | Report Code: TIPMD00002009 | No. of Pages: 133 | Category: Medical Device | Status: Published
Get more information on this report :
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of death related to cancer in the US and is expected to be the second leading cause of death by 2020. According to Cancer Research UK, approximately 9,921 new cases of pancreatic cancer were diagnosed in the UK in 2015, while 8,912 patients died due to same cancer. The cancer is almost always fatal and thus demands potential therapies for the patients’ treatment. For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US. According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US. The increasing incidence and prevalence of pancreatic cancer are expected to increase the demand for drugs, therapies, and treatment of patients. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the global pancreatic cancer therapy market over the forecast years.
Based on type, the pancreatic cancer therapy market is segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this type of cancer is the most common and majorly occurring type and thus is expected to have massive patient pool over the forecast years.
Get more information on this report :
Based on therapy, the pancreatic cancer therapy market is segmented into biologic therapy, chemotherapy, and others. In 2017, biologic therapy segment held the largest share of the market, by therapy. Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.
|Market Size Value in||US$ 2011.2 Million in 2017|
|Market Size Value by||US$ 4056.4 Million by 2025|
|Growth rate||CAGR of 8.1% from 2018-2025|
|No. of Pages||133|
|No. of Tables||43|
|No. of Charts & Figures||95|
|Historical data available||Yes|
|Segments covered||Type , Therapy and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Organic strategies are the more commonly adopted strategies by companies in the pancreatic cancer therpay market, which enables them expand their global footprints, and product and service portfolios. The market players have also adopted organic strategies such as product approvals, clinical trials and others strategies have enabled them to enlarge their global customer base, which also permits them to maintain their brand name globally.